13F Holdings
中文EN

IGC IGC Pharma, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1326205 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.9%
TTM net income YoY-25.8%
TTM EPS YoY7.4%
Revenue 3-yr CAGR-2.1%
Net income 3-yr CAGR—

Margins

Gross margin16.5%
Operating margin-802.7%
Net margin-643.7%
FCF margin-415.2%
EBITDA margin-786.5%

Returns

ROE-111.1%
ROA-83.3%
ROIC (approx.)-120.6%
Asset turnover0.13x

Leverage & solvency

Liabilities / assets33.2%
Debt / equity0.00x
Current ratio0.42x
Interest coverage-1,685.67x

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-29.8%
Payout ratio—
Capex / revenue1.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31FY20212021-03-31
Income statement
Revenue$1.27M$1.34M$911,000$397,000$898,000
Cost of revenue$652,000$612,000$469,000$203,000$785,000
Gross profit$619,000$733,000$442,000$194,000$113,000
R&D expense$3.65M$3.77M$3.46M$2.33M$929,000
SG&A expense$4.41M$6.76M$8.55M$13.29M$7.91M
Operating income-$7.45M-$9.80M-$11.57M-$15.43M-$8.72M
Interest expense$5,000$5,000$5,000$5,000$3,000
Pretax income-$7.12M-$13.00M-$11.51M-$15.02M-$8.81M
Income tax$0$0$0$0$0
Net income-$7.12M-$13.00M-$11.51M-$15.02M-$8.81M
EBITDA-$6.83M-$9.16M-$10.91M-$14.78M-$8.25M
EPS (basic)-0.09-0.22——-0.21
EPS (diluted)-0.09-0.22——-0.21
Weighted avg. shares (diluted)76.52M58.84M——41.96M
Balance sheet
Cash & equivalents$405,000$1.20M$3.20M$10.46M$14.55M
Short-term investments$0$0$154,000$0$80,000
Receivables$34,000$39,000$107,000$125,000$175,000
Inventory$1.36M$1.54M$2.65M$3.55M$5.48M
Current assets$2.90M$3.71M$6.47M$15.11M$23.52M
PP&E, net$3.22M$3.69M$8.21M$9.42M$10.84M
Intangibles$1.85M$1.62M$1.17M$917,000$407,000
Total assets$8.75M$9.90M$17.18M$26.83M$35.87M
Current liabilities$2.26M$2.34M$1.90M$2.44M$2.37M
Short-term debt$3,000$3,000$3,000$3,000$304,000
Long-term debt$134,000$137,000$141,000$144,000$276,000
Total debt$137,000$140,000$144,000$147,000$580,000
Total liabilities$2.42M$2.58M$2.27M$2.94M$3.06M
Shareholders' equity$6.33M$7.32M$14.91M$23.89M$32.80M
Net debt-$268,000-$1.06M-$3.05M-$10.31M-$13.97M
Shares outstanding80.88M66.69M53.08M51.05M47.83M
Cash flow statement
Operating cash flow-$4.79M-$5.20M-$7.05M-$7.46M-$10.80M
Capital expenditure$112,000$138,000$310,000$236,000$1.47M
Free cash flow-$4.91M-$5.34M-$7.36M-$7.70M-$12.27M
Investing cash flow-$442,000-$317,000-$235,000-$742,000$3.39M
Financing cash flow$4.45M$3.52M$100,000$4.14M$14.69M
Depreciation & amortization$618,000$637,000$657,000$651,000$478,000
Stock-based compensation$1.64M$1.77M$2.84M$2.20M$658,000

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.